Beta Bionics Inc. (BBNX)
| Bid | 9.88 |
| Market Cap | 438.26M |
| Revenue (ttm) | 48.59M |
| Net Income (ttm) | -55.37M |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -7.9 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.25 |
| Volume | 98,670 |
| Avg. Volume (20D) | 643,156 |
| Open | 11.25 |
| Previous Close | 10.91 |
| Day's Range | 10.06 - 11.28 |
| 52-Week Range | 8.89 - 24.50 |
| Beta | 0.00 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adher...
Analyst Forecast
According to 6 analyst ratings, the average rating for BBNX stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 167.06% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOsFive IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...